semaglutide cardiovascular outcomes study news and in Obesity without Diabetes: @NEJM The select trial: #AHA23 🥸Wow! @AHA_Research 😱Now on the stage in main event 😱Let's get the highlights 👇👇👇 SELECT: Glucagon-like peptide-1 receptor agonist

Because the data in the TriNetX platform is HIPAA de-identified, and therefore, by definition is deemed to allow no access to protected health information (and therefore no risk of protected health information disclosure), Institutional Review Boards (IRBs) have no jurisdiction of studies using HIPAA de-identified data (IRB factsheet for print 4-23-04.p65 (nih.gov) [24])

Person-years refers to both the number of people in a study and the length of time researchers tracked their health

Wang 11 , Y

Current evidence shows no increased pancreatic cancer risk with GLP-1 medications

The average (arithmetic mean) cost of developing a new drug is severely inflated due to a few exceedingly high-cost drugs